ILF/Co-Infections Thematic Roundtable on the Road to HCV Eradication

20 July 2015 | Vancouver, Canada (By invitation only)

Dramatic treatment advances for HCV are taking place; direct acting antivirals represent opportunities to cure most HCV-infected individuals. These new therapies offer improvements in sustained virologic response rates, ease of administration, reduced toxicity and shortened duration of treatment, resulting in declarations that HCV could soon be eradicated. Lessons learned from the HIV epidemic will be critical in reaching this ultimate goal of eradicating HCV infection.

This ILF/Co-Infections Thematic Roundtable took a step further from the 2nd International HIV/Viral Hepatitis Co-Infection Meeting (www.coinfectionmeeting.com) and focused on the development of a general, visionary and long-term agenda for HCV eradication. It addressed issues around (1) identifying of HCV-infected individuals and reaching key populations (particularly people who inject drugs and men who have sex with men); (2) establishing treatment priorities (e.g., whether or not to prioritize HIV/HCV co-infected individuals); (3) developing new financing models (particularly for middle-income countries); (4) supporting community empowerment; and (5) taking advantage of lessons learned from HIV.



Meeting material

  • Related documents
  • Presentations
  • Multimedia

Introduction
Kenneth Mayer, Fenway Institute, United States – ILF Co-Chair and Jürgen Rockstroh, University of Bonn, Germany – HIV Co-Infections Co-Chair / ILF Advisory Group member

Presentation

Global HCV Treatment Expansion: A Gilead Sciences Update
Gregg Alton, Gilead Sciences, United States

Presentation

Overview presentation I: Highlights from the 2nd International HIV/Viral Hepatitis Co-infection Meeting
Marina Klein, McGill University, Canada - HIV Co-Infections Co-Chair

Presentation

Overview presentation II: WHO Global Hepatitis Strategy – HCV epidemiology, treatment access and elimination targets
Gottfried Hirnschall, WHO, Switzerland

Presentation

Roundtable discussion: Challenges and opportunities along the road to HCV eradication
Facilitator: Paul Schaper, MSD, United States – ILF Advisory Group member

Presentation

  1. Identifying HCV-infected individuals and reaching key populations
    Nikos Dedes (Positive Voice, Greece)
  2. Establishing treatment priorities
    Isabelle Andrieux-Meyer (MSF, Switzerland)
  3. Developing new financing models (focus on middle-income countries)
    Robert Matiru (UNITAD, Switzerland)
  4. Supporting community empowerment
    Tracy Swan (Treatment Action Group, USA)
  5. Taking advantage of lessons learned from HIV
    Mauro Schechter (Universidade Federal do Rio de Janeiro, Brazil)
     

Summary and action points
Kenneth Mayer, Fenway Institute, United States – ILF Co-Chair, Jürgen Rockstroh, University of Bonn, Germany – HIV Co-Infections Co-Chair / ILF Advisory Group member and Sébastien Morin, International AIDS Society, Switzerland – ILF Research Officer

Presentation

Photo gallery